Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAS-MSA study of Emrusolmin in multiple system atrophy
2023-505320-54-00Phase 2Authorised
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing Emrusolmin with Placebo comparator (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Jan 2025; status: authorised.
02
Drugs
emrusolmin
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2023-505320-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505320-54-00.